Abstract: The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.

Abstract: A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.

Abstract: The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.

Abstract: The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.

Abstract: The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 ?m, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.

Abstract: The present disclosure provides for topical emulsion comprising about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; and about 0.4% to about 4% carbomer; wherein particles comprising the Montelukast in the emulsion have D90 of less than about 50 ?m, wherein the Montelukast or pharmaceutically acceptable salt thereof is homogeneously dispersed in the emulsion, and wherein the emulsion has a pH of about 3.0 to about 6.5. The present disclosure also provides a topical gel comprising (a) about 0.5% to about 10% Montelukast or pharmaceutically acceptable salt thereof; (b) about 0.2% to about 8% cellulose polymer; and (c) about 80% to about 95% amphiphilic compound; wherein the gel comprises less than 4% water.

Abstract: A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.

Abstract: A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.

Abstract: The present invention discloses therapeutic natural products, in particular plant extracts effective in treating and preventing urinary tract disorders, and method for obtaining said extracts. In particular, the present invention discloses a water-soluble alcoholic extract of Opuntia ficus-indica flower (NABIA extract), a component thereof (NABIA fraction) or any mixture of components thereof, which is substantially free of non water-soluble residues, and exhibits an effective alpha-1-adrenergic receptor blocking activity. Further are disclosed methods of preparing this extract and methods of inhibiting alpha-1-adrenergic receptors and/or 5-alpha-reductase, as well as of treating medical conditions associated therewith, such as urinary tract disorders.

Abstract: Color-changing cosmetic or therapeutic compositions for topical application are provided, comprising one or more active substances and one or more microencapsulated colorants, which upon application on the skin provide a changing color effect that indicates the delivery of the active substances from said composition onto the skin and/or gives to the skin a visual esthetical effect.

Abstract: The present invention provides methods for microencapsulation of active ingredients for topical application, whereby double-layer and triple-layer microcapsules are obtained. The microcapsules protect the active ingredients, maintain their original activity throughout processing, formulation and storage, and enable controlled release of the active ingredient only upon application onto the skin.

Abstract: The present invention discloses therapeutic natural products, in particular plant extracts effective in treating and preventing urinary tract disorders, and method for obtaining said extracts. In particular, the present invention discloses a water-soluble alcoholic extract of Opuntia ficus-indica flower (NABIA extract), a component thereof (NABIA fraction) or any mixture of components thereof, which is substantially free of non water-soluble residues, and exhibits an effective alpha-1-adrenergic receptor blocking activity. Further are disclosed methods of preparing this extract and methods of inhibiting alpha-1-adrenergic receptors and/or 5-alpha-reductase, as well as of treating medical conditions associated therewith, such as urinary tract disorders.

Abstract: The present invention provides methods for microencapsulation of active ingredients for topical application, whereby single-layer and multi-layer, preferably double-layer, microcapsules, are obtained. The microcapsules protect the active ingredients, maintain their original activity throught processing, formulation and storage, and enable controlled release of the active ingredient only upon application onto the skin.